Wegovy insurance coverage depends heavily on your plan type: many employer and commercial plans cover it with prior authorization, ACA Marketplace plans rarely cover it for weight loss alone, and Medicare now offers a narrow path through the new GLP-1 Bridge program. Your first move is to check your plan’s drug formulary and prior-authorization criteria before you schedule a visit, since that single step tells you what documentation your prescriber needs to submit.
TL;DR:
- Employer and commercial plans may exclude anti obesity drugs despite covering specialty medications, while only about 1% of Marketplace plans covered Wegovy in 2024.
- Approval often requires a BMI of 30 or higher, or 27 or higher with a related condition, plus clinical records and evidence of lifestyle changes.
- Plans may require trying a cheaper medication first, and renewals every six to twelve months often depend on documented weight loss during treatment.
- Eligible Medicare beneficiaries can pay a $50 Bridge copay, but those payments do not count toward Part D deductibles or out of pocket limits.
Coverage for Wegovy varies so much by payer type that the question “does insurance cover Wegovy” does not have one answer. It has at least five, depending on whether you have employer coverage, a Marketplace plan, Medicare, Medicaid, or military health benefits.
Commercial and employer-sponsored plans treat anti-obesity medications as an optional benefit, not a guaranteed one. Some large employers add Wegovy to their formulary, while others carve it out entirely. Because the decision sits with the employer, a seemingly generous plan can still exclude it. The plan’s summary plan description is the document that settles it, and it often contains language specifically excluding anti-obesity drugs even when other specialty medications are covered. When Wegovy is covered, prior authorization is almost always required.
ACA Marketplace plans are the toughest spot for coverage. According to KFF’s analysis of federal formularies, only about 1% of Marketplace prescription drug plans covered Wegovy in 2024, while Ozempic, the same medication’s diabetes-indicated version, was covered far more often. If you buy your own plan through healthcare.gov or a state exchange, assume Wegovy is excluded unless your plan’s formulary explicitly states otherwise.
Medicare historically excluded weight-loss drugs from Part D by statute, but 2026 changed that picture. The Centers for Medicare & Medicaid Services created the Medicare GLP-1 Bridge, a program that gives eligible beneficiaries access to Wegovy outside the normal Part D payment structure. We cover the Bridge’s mechanics in detail further down, but the short version is that it opens a door for Medicare beneficiaries who previously had none.
Medicaid coverage is a patchwork that depends entirely on your state. Some state Medicaid programs cover GLP-1 drugs for obesity, others cover them only for type 2 diabetes, and a few exclude anti-obesity indications altogether. Coverage tends to track whether the drug is prescribed for an FDA-approved metabolic condition rather than for weight loss alone, a pattern KFF’s policy analysis also found in commercial and Marketplace plans.
VA and TRICARE coverage policies vary by facility and by beneficiary category, so veterans and military families should confirm current formulary status directly with their pharmacy benefits manager rather than assume a blanket rule.
A few practical starting points, regardless of your plan type:
Insurers that do cover Wegovy almost universally require prior authorization, and the criteria tend to follow a consistent pattern even though exact thresholds vary by payer.
Most plans look for a body mass index of 30 or higher, or 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or high cholesterol. The CDC’s adult BMI calculator is the reference tool most plans point to for confirming where a patient falls. Beyond obesity alone, coverage pathways have broadened to include specific indications: type 2 diabetes, cardiovascular risk reduction, obstructive sleep apnea, and metabolic dysfunction-associated steatohepatitis (MASH). The cardiovascular pathway matters more than it might seem, since the FDA’s approval of Wegovy to reduce the risk of major cardiovascular events in adults with obesity or overweight gave payers a new, clinically distinct reason to approve the drug beyond weight loss alone.
A prior authorization request that gets approved on the first try typically includes:
Step therapy is common, meaning some plans want proof that a less expensive option was tried first, or that it was contraindicated, before approving Wegovy. If your plan substitutes a different GLP-1 formulation on its preferred formulary, your prescriber may need to document why that substitute is not appropriate for you.
Reauthorization typically happens every six to twelve months, and this is where many patients get caught off guard. Insurers generally want evidence that the patient hit a measurable weight-loss benchmark during the covered period. Clinics that track weight consistently and submit that data proactively tend to have an easier time at renewal than those that wait for the insurer to ask.
Pro Tip: Ask your prescriber’s office to document your weight at every visit from day one, even before you start Wegovy, so you have a clean baseline-to-progress record ready for reauthorization.
What you pay for Wegovy depends less on the drug’s list price and more on your specific plan design: your deductible phase, your coinsurance percentage, and whether Wegovy sits on a specialty tier.
If you have not met your annual deductible, you may owe the full negotiated rate for your first fills until the deductible resets. Plans that classify Wegovy as a preferred specialty drug tend to charge a lower flat copay, while non-preferred tier placement usually means higher coinsurance.
For eligible Medicare beneficiaries, the Medicare GLP-1 Bridge sets a $50 copay for Wegovy, a fixed and predictable amount that applies outside the normal Part D benefit structure, meaning those payments do not count toward your Part D deductible or true out-of-pocket (TrOOP) threshold.
Manufacturer savings programs can meaningfully lower near-term costs for commercially insured patients. The Wegovy Savings Offer and pharmacy resources through NovoCare are designed for people with commercial insurance that already covers the drug but leaves a copay or coinsurance balance; these savings cards typically cannot be used by Medicare or Medicaid beneficiaries because federal health program rules restrict manufacturer copay assistance in those programs.
A few cost factors worth comparing side by side before you fill a prescription:
If your plan does not cover Wegovy at all, the cash price is often the highest-cost route, which is exactly why checking formulary status before your first visit matters more than almost any other step in this process.
Getting Wegovy covered is rarely passive. It takes a specific sequence of calls, documents, and follow-up, and knowing that sequence before you start saves weeks.
Start with these immediate steps:
Your prescriber’s office handles the clinical submission, and a complete package typically includes the diagnosis codes tied to your covered indication, your weight history and current BMI, documentation of lifestyle modification program participation, and notes on any prior medications tried. Missing documentation is the single most common reason a request gets delayed rather than denied outright, so a complete first submission saves time even if it takes an extra day to assemble.
If your prior authorization is denied, you have the right to an internal appeal, which your insurer must process within a set timeframe defined by your plan type and state law. If the internal appeal also fails, you can request an external review conducted by an independent third party, a step that in many states must be completed within weeks rather than months. Appeals succeed more often when they include new or strengthened clinical evidence, such as updated weight and BMI records, documentation of a qualifying comorbidity that was not initially submitted, or a peer-to-peer conversation between your prescriber and the insurer’s medical director.
Pro Tip: Keep a dated folder of every denial letter, phone call reference number, and resubmission, since appeals move faster when you can show a clear paper trail rather than re-explaining your case from scratch each time.
If your appeal still fails and cost remains a barrier, patient assistance programs and manufacturer resources are worth exploring before giving up on the medication entirely. For Medicare beneficiaries specifically, confirming your Part D plan’s formulary and appeal rights is easier with the right guidance. A partner guide to choosing a Medicare Part D plan walks through how to compare plan formularies and appeal processes if you are weighing your options during an enrollment period.
The Medicare GLP-1 Bridge is the most significant change to Wegovy access for older adults in years, and it operates differently from a standard Part D fill, which trips up a lot of beneficiaries and even some pharmacies.
The CMS prescriber guidance for the Bridge confirms that Wegovy, in all its formulations, is included in the program, alongside other GLP-1 medications used to reduce excess body weight. Not every GLP-1 product on the market is included in the same way, so confirming your specific drug and formulation against the current Bridge list before assuming coverage is worth the extra call.
Key mechanics beneficiaries and pharmacies should understand:
If you are a Medicare beneficiary interested in Wegovy, the most efficient first step is asking your prescriber’s office whether they have already processed a Bridge request before, since the submission process differs enough from routine Part D prior authorizations that unfamiliarity causes avoidable denials.
Getting from “I want to try Wegovy” to “my insurance approved it” usually means juggling a telehealth visit, a formulary check, and a prior-authorization packet across three different phone calls. We built our weight-loss service to collapse that into one place.
Through AM Rx’s weight-loss care, we handle the telehealth visit, run an insurance benefits check against your plan’s formulary, and help assemble the documentation your prescriber needs for a prior-authorization request, including diagnosis codes, weight history, and lifestyle program notes. We also coordinate directly with pharmacies so your prescription moves without you having to re-explain your case at each step, and deliver approved prescriptions to your door once coverage clears.
If your plan requires reauthorization down the line, we track your weight-loss progress visit over visit, so that documentation is ready when your insurer asks for it. For patients managing early side effects while a prior authorization is pending, our guide on managing GLP-1 nausea covers practical steps that come up often in the first weeks of treatment.
Most coverage guides treat prior authorization like a bureaucratic hoop to clear once and forget. That is the wrong mental model. Reauthorization, not initial approval, is where coverage most often quietly lapses, because patients and clinics stop tracking weight data the moment the first approval comes through.
The Medicare GLP-1 Bridge gets outsized attention because it is new, but the bigger practical issue for most readers is still the employer plan exclusion buried in a summary plan description nobody reads until a claim gets denied. If you take one thing from this guide, make it this: read your plan’s anti-obesity medication clause before your first visit, not after your first denial. That single habit prevents more wasted appeals than any documentation checklist ever will.
— Bryan
We make the first step simple: book a telehealth visit, and we run your insurance check and prior-authorization groundwork at the same time, so you are not waiting on separate calls to find out where you stand.
What you get when you start with AM Rx’s weight-loss service:
Book your visit today and begin the process of checking where your plan stands on Wegovy coverage.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
Coverage for weight-loss medications, including pills and injectables, depends on your specific plan and varies widely by payer type. Employer and commercial plans sometimes cover them with prior authorization, while ACA Marketplace plans rarely cover GLP-1 drugs for weight loss alone. Checking your plan’s formulary directly is the only reliable way to know.
A prescriber typically will not prescribe a GLP-1 medication like Wegovy if you do not meet the clinical criteria, such as a BMI below the plan’s threshold with no qualifying comorbidity, or if you have a personal or family history of certain thyroid cancers or other contraindications your provider screens for during your visit. Insurance denial for lack of documented medical necessity is a separate, more common reason coverage gets refused even when the prescription itself is appropriate.
GoodRx is a discount card service, not insurance, so it does not provide coverage in the way a health plan does. It can sometimes lower the cash price at the pharmacy counter, but it works separately from manufacturer savings offers and from your insurance formulary status, so comparing all three options before filling is worthwhile.
Medicare Part D historically did not cover Wegovy for weight loss alone, but the new Medicare GLP-1 Bridge now gives eligible beneficiaries access to Wegovy at a $50 copay outside the standard Part D payment flow. Eligibility depends on meeting the clinical criteria CMS prescriber guidance outlines, including BMI thresholds and qualifying diagnoses.
Start with an internal appeal through your insurer, which must be processed within a timeframe set by your plan and state law, and include any additional clinical documentation that strengthens your case. If the internal appeal is denied, you can request an external review by an independent third party, a process available in every state for health plan denials.
These are the primary sources we relied on for the policy and coverage details in this guide, useful if you want to confirm current rules directly or walk through official forms with your provider.
